Tickers

1. Composite Trajectory Verdict

For a professional services company like EPAM, the income statement and cash flow statement carry the most weight because profitability margins and cash conversion from services revenue are the primary indicators of operational health; the balance sheet is secondary but relevant for liquidity and capital allocation capacity.

Composite Trajectory: Mixed

The annual 2025 results show revenue growth of 15.4% but operating income declining 4.5% and net income falling 16.9%, with operating margin compressing from 11.5% to 9.5% (10-K 2025-12-31, Consolidated Statements of Operations). In contrast, the most recent quarter (Q2 2026) and year-to-date periods show revenue growth of 4.5% and 6.0% respectively, with operating income rising 20.4% and 19.1%, and operating margins expanding to 10.8% and 9.6% (10-Q 2026-06-30, Consolidated Statements of Operations). Cash flow from operations increased 17.1% for full-year 2025 but turned negative (-$38.8 million) in the first half of 2026 versus +$77.4 million in the prior year (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Consolidated Statements of Cash Flows). The balance sheet remains low-leverage with ample revolver capacity, though cash has been deployed aggressively for share repurchases ($660.6 million in FY2025, $409.0 million in H1 2026) (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).

2. Red Flags

• Annual operating margin compressed 200 basis points (11.5% to 9.5%) despite 15.4% revenue growth, as cost of revenues grew 18.5% and D&A rose 39.4% (10-K 2025-12-31, Consolidated Statements of Operations).
• Annual net income fell 16.9% ($454.5 million to $377.7 million) while revenue rose (10-K 2025-12-31, Consolidated Statements of Operations).
• Year-to-date 2026 operating cash flow was negative $38.8 million versus positive $77.4 million in H1 2025, driven by higher variable compensation payments and increased days sales outstanding (10-Q 2026-06-30, Consolidated Statements of Cash Flows; MD&A).
• Cash and cash equivalents dropped 39% from $1.296 billion at year-end 2025 to $789.4 million at June 30, 2026, largely due to $409.0 million of share repurchases in H1 2026 exceeding operating cash generation (10-Q 2026-06-30, Consolidated Balance Sheets; MD&A).
• Accrued compensation and benefits rose 25.4% year-over-year to $608.2 million at December 31, 2025, then fell 18.5% to $496.0 million at June 30, 2026, reflecting large annual bonus payouts (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Consolidated Balance Sheets).
• Effective tax rate increased from 22.2% to 25.3% for FY2025 and from 26.0% to 29.0% for H1 2026 (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Consolidated Statements of Operations).
• Foreign exchange losses widened to $25.9 million in FY2025 from $7.0 million in FY2024, and to $9.9 million in Q2 2026 from $6.2 million in Q2 2025 (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Consolidated Statements of Operations).
• Interest and other income declined from $46.9 million to $11.5 million annually and turned negative in Q2 2026 (-$1.8 million vs +$3.5 million) (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Consolidated Statements of Operations).
• Share repurchases in H1 2026 ($409.0 million) exceeded operating cash flow (-$38.8 million), funded by drawing down cash reserves (10-Q 2026-06-30, MD&A; Consolidated Statements of Cash Flows).
• Humanitarian aid commitment for Ukraine continues with $4.6 million remaining to be expensed as of June 30, 2026 (10-Q 2026-06-30, MD&A).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Full-year 2025 revenue grew 15.4% to $5.457 billion but operating income fell 4.5% to $520.0 million and net income declined 16.9% to $377.7 million, with diluted EPS dropping from $7.84 to $6.72 (10-K 2025-12-31, Consolidated Statements of Operations). Cost of revenues rose 18.5% to 71.2% of revenue, while SG&A grew 13.8% to 17.0% of revenue; D&A jumped 39.4% to $124.8 million due to acquisition amortization (10-K 2025-12-31, MD&A). However, the most recent quarter (Q2 2026) shows improvement: revenue rose 4.5% to $1.415 billion, operating income increased 20.4% to $152.2 million, and net income grew 17.0% to $103.0 million, with operating margin expanding to 10.8% from 9.3% (10-Q 2026-06-30, Consolidated Statements of Operations). Year-to-date 2026 operating margin improved to 9.6% from 8.5% in H1 2025, driven by cost of revenues falling to 71.0% of revenue from 72.2% (10-Q 2026-06-30, Consolidated Statements of Operations). Segment trends diverge: Americas segment operating margin improved to 18.8% in Q2 2026 from 16.4% in Q2 2025, while Europe segment margin rose to 16.1% from 14.3% (10-Q 2026-06-30, MD&A).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

FY2025 operating cash flow increased 17.1% to $654.9 million from $559.2 million in FY2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). Investing cash outflows normalized to $49.0 million in FY2025 after $885.0 million in FY2024 (which included $912.2 million for acquisitions) (10-K 2025-12-31, Consolidated Statements of Cash Flows). Financing outflows rose to $651.2 million in FY2025 from $390.4 million, driven by $660.6 million of share repurchases versus $398.0 million (10-K 2025-12-31, MD&A). In H1 2026, operating cash flow turned negative (-$38.8 million) versus +$77.4 million in H1 2025, attributed to higher variable compensation payments and a larger increase in days sales outstanding (10-Q 2026-06-30, Consolidated Statements of Cash Flows; MD&A). H1 2026 share repurchases totaled $409.0 million (including $300 million ASR), contributing to a $507.1 million net decrease in cash (10-Q 2026-06-30, MD&A; Consolidated Statements of Cash Flows). Capital expenditures were $33.1 million in H1 2026 versus $19.2 million in H1 2025 (10-Q 2026-06-30, MD&A). The company maintains $675.0 million of available revolver capacity with $25.0 million drawn as of June 30, 2026 (10-Q 2026-06-30, MD&A).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Stable

Total assets grew 3.2% to $4.902 billion at December 31, 2025 from $4.750 billion a year earlier, with cash stable at $1.296 billion and trade receivables rising 10.6% to $1.108 billion (10-K 2025-12-31, Consolidated Balance Sheets). Goodwill increased to $1.211 billion from $1.182 billion, while intangibles declined to $406.6 million from $436.4 million (10-K 2025-12-31, Consolidated Balance Sheets). Total liabilities rose 9.4% to $1.224 billion, driven by a 19.0% increase in current liabilities to $976.9 million, primarily from accrued compensation growing 25.4% to $608.2 million (10-K 2025-12-31, Consolidated Balance Sheets). Long-term debt remained minimal at $25.0 million (10-K 2025-12-31, Consolidated Balance Sheets). By June 30, 2026, total assets decreased to $4.574 billion, cash fell to $789.4 million, and receivables rose to $1.268 billion (10-Q 2026-06-30, Consolidated Balance Sheets). Current liabilities declined to $804.4 million with accrued compensation dropping to $496.0 million, reflecting seasonal bonus payments (10-Q 2026-06-30, Consolidated Balance Sheets). Total equity decreased to $3.519 billion from $3.678 billion due to share repurchases reducing retained earnings and share count (51.585 million shares vs 54.274 million) (10-Q 2026-06-30, Consolidated Balance Sheets). Leverage remains negligible; liquidity (cash + revolver) of ~$1.46 billion exceeds current liabilities of $804 million (10-Q 2026-06-30, Consolidated Balance Sheets; MD&A).

6. Data Gaps

• Standalone Q1 2026 quarterly results (only YTD Q2 and Q2 quarterly data provided in 10-Q 2026-06-30).
• Q3 2026 and Q4 2026 results (not yet filed).
• Full FY2023 income statement details (10-K 2025-12-31 only shows FY2023 revenue in the three-year revenue table).
• Segment operating profit for quarters prior to Q2 2025 (only Q2 2026 and Q2 2025 shown in 10-Q 2026-06-30).
• Detailed cash flow statement for Q2 2026 standalone (10-Q 2026-06-30 XBRL cash flow data truncated in provided filing).
• Breakdown of cost of revenues components (salaries, subcontractors, travel, etc.) beyond aggregate MD&A discussion.
• Contingent consideration fair value changes and earn-out terms for recent acquisitions (NEORIS, First Derivative).
• Full schedule of debt maturities and covenant details beyond revolver capacity.